SavedAdd your journal

Journals / art / 2020 / Cilt: 35 - Sayı: 1

A Retrospective, Cross-Sectional Study on the Prevalence of Hyperuricemia Using a Japanese Healthcare Database

Shingo HIGA
Mizuki YOSHIDA
Daisuke SHIMA
Yoichi II
Shigeru KITAZAKI
Yuji YAMAMOTO
Yoko FUJIMOTO
Journal
art
Pages
41–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is important to increase the awareness on HU in thesociety to reduce the burden of HU-related diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the prevalence of hyperuricemia (HU) considering both serum uric acid (SUA) levels and medication statusof urate-lowering drugs (ULDs), and the association between HU and its comorbidities using a Japanese healthcare database.Materials and Methods: The study population consisted of 60,828 subjects who had at least one serum uric acid measurement between thefiscal years (FYs) 2010 and 2014 in a Japanese employment-based health insurance database (MinaCare Co., Ltd., Tokyo, Japan), which includesmutually linked medical/pharmaceutical claims data and health check-up data.
📊
Key Findings & Data:Hyperuricemia was defined as a SUA level >7.0 mg/dL of the healthcheck-up data and/or a prescription for a ULD.
💡
Conclusion & Impact:It is important to increase the awareness on HU in thesociety to reduce the burden of HU-related diseases.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to evaluate the prevalence of hyperuricemia (HU) considering both serum uric acid (SUA) levels and medication statusof urate-lowering drugs (ULDs), and the association between HU and its comorbidities using a Japanese healthcare database.Materials and Methods: The study population consisted of 60,828 subjects who had at least one serum uric acid measurement between thefiscal years (FYs) 2010 and 2014 in a Japanese employment-based health insurance database (MinaCare Co., Ltd., Tokyo, Japan), which includesmutually linked medical/pharmaceutical claims data and health check-up data. Hyperuricemia was defined as a SUA level >7.0 mg/dL of the healthcheck-up data and/or a prescription for a ULD. The association between HU and comorbidities were analyzed by comparing the prevalence of HU ofeach subgroup defined by presence or absence of comorbidity.Results: The prevalence of HU in FY 2014 was 26.8% (95% confidence interval [CI]: 26.2 to 27.3%) in male subjects and 0.9% (95% CI: 0.7 to 1.0%)in female subjects. According to the analyses by sex and age, a trend of increasing prevalence with age was observed in both males and females.The prevalence of HU remained stable both in males and females from FYs 2010 to 2014. The positive association between HU and well-knowncomorbidities were confirmed with the exception of diabetes mellitus and smoking status in male subjects.Conclusion: Our results provided a more accurate prevalence of HU in Japanese population. It is important to increase the awareness on HU in thesociety to reduce the burden of HU-related diseases.

🔖

Cite This Article

HIGA, S., YOSHIDA, M., SHIMA, D., II, Y., KITAZAKI, S., YAMAMOTO, Y., FUJIMOTO, Y. (2020). A Retrospective, Cross-Sectional Study on the Prevalence of Hyperuricemia Using a Japanese Healthcare Database. art, Cilt: 35 - Sayı: 1, 41–51. https://ajindex.com/articles/351643

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6
  2. Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One 2014;9:e114259
  3. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102-10
  4. Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One 2014;9:e100801
  5. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009;169:342-50
  6. Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol 2014;2014:852954
  7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
  8. Fujimori S, Itoh H, Kato K, Watanabe H, Matsuura H, Ogata N, et al. The frequencies of hyperuricemia and gout may not increase in Japan. Gout and Nucleic Acid Metabolism 2006;30:13-20
  9. Kamei K, Konta T, Ichikawa K, Sato H, Suzuki N, Kabasawa A, et al. Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study. Clin Exp Nephrol 2016;20:904-9
  10. Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol 2011;31:410-9
  11. Liu B, Wang T, Zhao HN, Yue WW, Yu HP, Liu CX, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health 2011:11:832
  12. Tomita M, Mizuno S. Is the number of patients with hyperuricemia increasing? - Focusing on gender differences. Gout Nucleic Acid Metab 2006;30:1-5
  13. Japanese Society of Gout and Nucleic Acid Metabolism Guideline Revisory Committee, ed. Revised Guideline for the Management of Hyperuricemia and Gout. Osaka: Medical Review Co. Ltd; 2010. p. 32-4
  14. Shima D, Ii Y, Yamamoto Y, Nagayasu S, Ikeda Y, Fujimoto Y. A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan. BMC Cardiovasc Disord 2014;14:120
  15. The Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan. Ethical Guidelines for Medical and Health Research Involving Human Subje